Literature DB >> 13631610

The analgesic equivalence to morphine and relative side action liability of oxymorphone (14-hydroxydihydro morphinone).

N B EDDY, L E LEE.   

Abstract

Entities:  

Keywords:  DIHYDROMORPHINONE/related compounds

Mesh：

Substances：

Year:  1959        PMID： 13631610

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN： 0022-3565            Impact factor:   4.030


× No keyword cloud information.
  7 in total

1.  Tests for addiction (chronic intoxication) of morphine type.

Authors:  H HALBACH; N B EDDY
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

2.  Study on the activation of the opioid receptors by a set of morphine derivatives in a well-defined assay system.

Authors:  Yan Zhang; Zhiwei Wang; D Phillip Cox; Olivier Civelli
Journal:  Neurochem Res       Date:  2011-10-16       Impact factor: 3.996

3.  To-day's Drugs.

Authors: 
Journal:  Br Med J       Date:  1963-01-26

4.  Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans.

Authors:  Shanna Babalonis; Michelle R Lofwall; Paul A Nuzzo; Sharon L Walsh
Journal:  Addict Biol       Date:  2014-07-31       Impact factor: 4.280

5.  Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study.

Authors:  Paul Sloan; Neal Slatkin; Harry Ahdieh
Journal:  Support Care Cancer       Date:  2004-11-09       Impact factor: 3.603

6.  Relative potency of intravenous oxymorphone compared to other µ opioid agonists in humans - pilot study outcomes.

Authors:  Shanna Babalonis; Sandra D Comer; Jermaine D Jones; Paul Nuzzo; Michelle R Lofwall; Jeanne Manubay; Kevin W Hatton; Robert A Whittington; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2021-06-01       Impact factor: 4.415

Review 7.  Practical management of opioid rotation and equianalgesia.

Authors:  Erwan Treillet; Sophie Laurent; Yacine Hadjiat
Journal:  J Pain Res       Date:  2018-10-29       Impact factor: 3.133
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.